Show simple item record

dc.contributor.authorJiménez-Marrero, Santiago
dc.contributor.authorCainzos-Achirica, Miguel
dc.contributor.authorMonterde, David
dc.contributor.authorGarcia-Eroles, Luis
dc.contributor.authorEnjuanes-Grau, Cristina
dc.contributor.authorYun, Sergi
dc.contributor.authorGaray, Alberto
dc.contributor.authorMoliner, Pedro
dc.contributor.authorAlcoberro, Lidia
dc.contributor.authorCorbella Virós, Xavier
dc.contributor.authorComin-Colet, Josep
dc.date.accessioned2020-10-27T17:42:14Z
dc.date.available2020-10-27T17:42:14Z
dc.date.issued2020
dc.identifier.citationJiménez-Marrero, Santiago; Cainzos-Achirica, Miguel; Monterde, David [et al.]. Real-world epidemiology of potassium derangements among chronic cardiovascular, metabolic and renal conditions: a population-based analysis. Clinical Epidemiology, 2020, 12, p. 941-952. Disponible en : <https://www.dovepress.com/real-world-epidemiology-of-potassium-derangements-among-chronic-cardio-peer-reviewed-article-CLEP>. Fecha de acceso: 27 oct. 2020. DOI: 10.2147/CLEP.S253745.ca
dc.identifier.issn1179-1349ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1694
dc.description.abstractBackground: The aims of the present analysis are to estimate the prevalence of five key chronic cardiovascular, metabolic and renal conditions at the population level, the prevalence of renin–angiotensin–aldosterone system inhibitor (RAASI) medication use and the magnitude of potassium (K+) derangements among RAASI users. Methods and Results: We used data from more than 375,000 individuals, 55 years of age or older, included in the population-based healthcare database of the Catalan Institute of Health between 2015 and 2017. The conditions of interest were chronic heart failure (CHF), chronic kidney disease (CKD), diabetes mellitus, ischemic heart disease and hypertension. RAASI medications included angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists (MRAs) and renin inhibitors. Hyperkalemia was defined as K+ levels > 5.0 mEq/L and hypokalemia as K+ < 3.5 mEq/L. The prevalence of chronic cardiovascular, metabolic and renal conditions was high, and particularly that of hypertension (prevalence ranging from 48.2% to 48.9%). The use of at least one RAASI medication was almost ubiquitous in these patients (75.2– 77.3%). Among RAASI users, the frequency of K+ derangements, mainly of hyperkalemia, was very noticeable (12% overall), particularly in patients with CKD or CHF, elderly individuals and users of MRAs. Hypokalemia was less frequent (1%). Conclusion: The high prevalence of K+ derangements, and particularly hyperkalemia, among RAASI users highlights the real-world relevance of K+ derangements, and the importance of close monitoring and management of K+ levels in routine clinical practice. This is likely to benefit a large number of patients, particularly those at higher risk.ca
dc.format.extent12ca
dc.language.isoengca
dc.publisherDovepressca
dc.relation.ispartofClinical Epidemiologyca
dc.relation.ispartofseries12;
dc.rightsThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.ca
dc.subject.otherInsuficiència cardíacaca
dc.subject.otherHipertensióca
dc.subject.otherPotassica
dc.subject.otherInsuficiència renal crònicaca
dc.subject.otherDiabetisca
dc.subject.otherInsuficiencia cardíacaca
dc.subject.otherHipertensiónca
dc.subject.otherPotasioca
dc.subject.otherInsuficiencia renal crónicaca
dc.subject.otherDiabetesca
dc.subject.otherHeart failureca
dc.subject.otherHypertensionca
dc.subject.otherPotassiumca
dc.subject.otherChronic renal failureca
dc.subject.otherDiabetesca
dc.titleReal-world epidemiology of potassium derangements among chronic cardiovascular, metabolic and renal conditions: a population-based analysisca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616ca
dc.subject.udc616.1ca
dc.subject.udc616.3ca
dc.subject.udc616.4ca
dc.identifier.doihttps://dx.doi.org/10.2147/CLEP.S253745ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record